Accordingly, and in a clinical study, the brain penetrant and highly potent H3R antagonist/inverse agonist GSK239512 was generally well tolerated, but failed to provide overall beneficial effects on cognitive impairments associated with SCH (Jarskog et al., 2015). The gene discussed is HRH3; the disease is spindle cell hemangioma.